Nurnberg, Germany

Manfred Marschall


 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Manfred Marschall: Innovator in Antiviral Strategies

Introduction

Manfred Marschall is a notable inventor based in Nurnberg, Germany. He has made significant contributions to the field of antiviral research, particularly in developing strategies to combat herpesviruses. His innovative work has led to advancements in the understanding and treatment of viral infections.

Latest Patents

Marschall holds a patent titled "Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses." This invention provides a novel NEC-targeted strategy for developing antiherpesviral drugs. It focuses on a unique antiviral approach that targets the viral-cellular nuclear egress complex (NEC) for small molecule-based therapy or prophylaxis. This strategy aims to control infections caused by human cytomegalovirus and other pathogenic viruses within the Herpesviridae family. The patent also outlines methods for screening agents, compounds, and small molecules that modulate or inhibit the nuclear egress complex of these viruses.

Career Highlights

Marschall is currently associated with Aicuris Anti-infective Cures AG, where he continues to contribute to the field of antiviral drug development. His work is pivotal in advancing therapeutic options for patients suffering from herpesvirus infections.

Collaborations

Marschall has collaborated with esteemed colleagues, including Yves Muller and Heinrich Sticht. These partnerships have enhanced the research and development efforts in the antiviral domain.

Conclusion

Manfred Marschall's innovative contributions to antiviral strategies highlight his role as a key figure in the fight against herpesviruses. His patent and ongoing work at Aicuris Anti-infective Cures AG demonstrate his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…